Serial dealmaker Cathal Friel: ‘It's not money that motivates me. I get fun out of creating something'
, the serial dealmaker who floated five companies in the past 13 years, is on an extended summer break of three weeks in Dunfanaghy on the northern coast of his native Co
Donegal
.
But the businessman, who started working at 16, is never fully switched off, agreeing to a midmorning interview with The Irish Times by videoconference from his rented cottage while his three teenage
children sleep in.
'I take busman's holidays. I like to check in with work every other day when on a break,' the 60-year-old says. 'The wifi coverage up here is great, which helps.'
Having stepped down last month as chairman of
Hvivo
, the clinical trials business whose precursor (Open Orphan) he listed six years ago, Friel has narrowed his focus – for now, at least – to what he calls 'two kindergarten-phase' companies originally hatched in his Raglan Capital incubator for listable companies.
READ MORE
These are
Poolbeg Pharma
, spun out of Hvivo in 2021, which is focused on developing a potentially breakthrough pill (known as POLB 001) to protect against certain negative reactions to cancer immunotherapies; and European Green Transition (EGT), whose interests currently comprise a Swedish rare earth minerals prospect and a Donegal project aimed at using peatland to generate carbon and biodiversity credits.
The aim is ambitious: to find the next Amryt Pharma, the biopharma company Raglan floated in 2016, which was bought two years ago by Italy's Chiesi Farmaceuti in a €1.4 billion deal (including follow-on payments after milestones were met). That firm developed a breakthrough therapy for a rare and painful skin disease, called epidermolysis bullosa, that mostly affects children.
Poolbeg, in which executive chairman Friel owns a 5.9 per cent stake, revealed on the first day of trading this year that it was in merger talks with Nasdaq-listed peer Hookipa Pharma, which was in the middle of major restructuring programme. However, Hookipa walked away in late February when its finances looked less precarious as it secured an almost €20 million of research grants from the Austrian government.
[
Poolbeg focuses on 'Plan B' after US merger talks collapse
Opens in new window
]
'Some of the best deals are the often ones you don't end up doing,' he says. 'I certainly wouldn't be in Donegal right now if it had gone through. I would have been spending most of my time in America trying to sort out that business.'
Friel said investors who took part in a virtual roadshow for an equity raise that was to take place immediately after a tie-up with Hookipa were mostly interested in the Irish company's 001 treatment.
Cathal Friel: 'If the trials are successful, Poolbeg will likely be bought out like Amryt. It could do really, really well.' Photograph: Alan Betson
'We met most of the 40 biggest North American biotech investors on that roadshow. Everyone was saying, 'Why are you getting involved with Hookipa? Focus on 001.' It has the potential to transform cancer treatment'.'
Poolbeg subsequently raised £4.7 million (€5.6 million) in an equity raise, mainly to get 001 ready for a key clinical trial – known as a Phase 2a trial – later this year to see if it can prevent cytokine release syndrome (CRS), a dangerous immune response triggered by certain cancer immunotherapies.
'We all became familiar with this syndrome during Covid-19, when cytokine storms caused immune systems to overreact and start attacking the body,' says Friel.
The stock market is yet to get excited, with Poolbeg shares off about 25 per cent so far this year. But Friel – a glass-half-full guy by nature – is hopeful. 'If the trials are successful, Poolbeg will likely be bought out like Amryt,' he says. 'It could do really, really well.'
EGT, in which Friel retains a 19 per cent stake after floating in April 2024, is at an even earlier stage.
It reported encouraging findings late last year from initial drilling at its Olserum rare earth project in Sweden. EGT does not intend to mine itself, but to find a buyer or a partner. It also has an exclusive option over the so-called Altan carbon credit project in Donegal, covering 1,370 acres of peatland. While it also took out an option early last year to buy into a project to extract copper left over from an abandoned Cypriot mine, it subsequently walked away to conserve capital.
'EGT is opportunist. We're looking for distressed assets that we can turn around,' he says. It's a focus that's served Raglan – which he co-owns with his wife, Pamela Iyers – well in its deal-making on the pharma sector over the years.
Friel says he made 'sub €10 million' from Amryt – a fraction what co-founder and chief executive Joe Wiley secured for his stock-options-driven interest.
The pay-day is broadly in line, he says, with what he made from Hvivo by the time he sold his last shares in that business a year ago.
'It's not money the motivates me. I get much more fun out of putting vehicles together and doing deals and creating something,' Friel insists. 'Creating too much wealth creates a problem as to how to pass on. I believe it's important not to hand too much easy money to the next generation. Working keeps all of us sane and not having to work can destroy lives.'
Tough start
The start Friel got would have broken many others. While his entrepreneurial father built up a petrol station in Creeslough, in north Donegal [
an explosion at that station
, which the Friel family sold out of decades ago, killed 10 people in 2022], a Ford dealership franchise for half the county and Irish cottage rental business during the 1970s, they were badly hit when interest rates spiked to almost 17 per cent in 1981 amid a surge in inflation.
Friel, the seventh of 10 children, had to leave school at 16 to run indebted businesses when his father became ill. It left him with a lifelong aversion to debt and property investment.
'I was in the wrong place at the wrong time in the family. The older kids were at university and the younger ones were behind me in school,' he says. 'I spent years dealing with the bank trying to pay down debt and get rid of things.'
He started doing night classes in computer programming with the regional technical college in Letterkenny, followed up by studying in his 20s for a degree and then a master's in business administration at Ulster University.
Friel was subsequently asked by the university to become a part-time lecturer of international marketing and business policy, which he did between 1990 and 1995. After selling off the family business in 1996, he took off backpacking for a year, during which he turned 32, to travel southeast Asia. This was funded in part by taking some money off the table as early small investor in insulation group Kingspan, which had floated in 1989.
Returning to Ireland on Good Friday 1998 – the date of the Belfast Agreement – Friel started sending out CVs. Following close to 50 interviews that summer, he was finally hired by businessman Jim Maher, founder of financial software company, Allfinanz. Friel worked for nothing for the first three months to get a foot in the door. A year later, he was Maher's deputy chief executive. Allfinanz would ultimately end up being acquired by German reinsurer Munich Re in 2007 for €48 million, long after Friel had departed.
Media deals
Following a stint working for a venture capital fund set up by Sean Melly, the late telecoms executive, Friel joined Merrion Capital's corporate finance unit in early 2001. 'It was another complete career reinvention and required a lot of fast learning,' he says.
He developed a niche in the media sector, selling local newspaper companies and radio stations. He advised on the likes of the €34 million sale of the Meath Chronicle in 2002 and UK media group Emap's €200 million disposal of Today FM, FM104 and Donegal's Highland Radio to Denis O'Brien's Communicorp in 2007.
Cathal Friel: 'I'm convinced that, just like with the arrival of the motorcar and the PC revolution, AI will create far more jobs than it eliminates.' Photograph: Alan Betson
He also worked with Scottish media group Johnston Press when it acquired Leinster Leader and Local Press groups for a combined €236 million. Friel says, however, that he recommended Johnston Press, which was on an acquisitions spree at the time, not do the deal, because of the mad price. 'But hats off to anyone that sold a radio station or regional newspaper at that time – because they did really, really well,' he said.
By the time the Emap deal was completed, Friel was already working part-time setting up Raglan Capital – which was initially set up to be part corporate finance boutique and part investment firm, targeting turnaround opportunities among companies listed on London's junior Alternative Investment Market (AIM).
At Raglan, he advised on the sale of the Sligo Champion to Independent News & Media (INM), now Mediahuis Ireland, in 2008 for a reported €25 million. 'That was the last helicopter out of Saigon for the sector, before valuations slumped,' he recalls. The last corporate finance transaction Raglan worked on was the sale of Galway businessman Gerry Barry's financial payments business Fintrax for €170 million in 2012.
By then, Raglan's focus was solely on putting together its own deals, often backed by the former owners of businesses he had sold during his Merrion days.
It started off in 2012 with Fastnet Oil & Gas, an exploration venture backed by top executives at Cove Energy, John Craven and Michael Nolan, as the Mozambique-focused business was being sold to Shell for €1.2 billion. Fastnet gained an AIM quotation by reversing into a listed cash shell.
The Government should double all existing housing height limits overnight in every part of the country, make it more difficult for people to object to new housing developments and ban all judicial reviews on residential planning decisions
—
Cathal Friel
Fastnet became involved in exploration in the Celtic Sea and off the Morocco coast. However, in the wake of an oil price collapse in 2014, Friel engineered a spin-off of the exploration assets and pivoted to the pharma sector. It did this by merging in 2016 with Amryt, a company Raglan had just set up with Wiley to focus on buying and developing drug candidates for rare and orphan diseases. The deal was essentially an initial public offering (IPO) as it involved a €12.6 million stock offering.
Friel backed away at that stage to allow Wiley and Amryt's chief financial officer, Rory Nealon, do their thing under chairman Ray Stafford, founder of Sudocrem. 'I always try to find really good CEOs and CFOs and not get in the way after that,' he says.
Still, he remained on the board until 2017 and a shareholder until Amryt's sale in 2023 – a deal that was driven by its transformational purchase in the interim of a much larger US company, Aegerion, out of bankruptcy. Aegerion had two regulator-approved drugs generating revenues at the time.
Hvivo
Friel, in the meantime, orchestrated the IPO of Open Orphan, a pharma services company, in 2019 through the reverse takeover of Dublin-listed Venn Life Sciences. The company went on later that year to buy UK clinical trials business Hvivo, which was struggling at the time, and went on to rename the group Hvivo in late 2022.
Hvivo's market value peaked at almost £260 million (€300 million) in early 2021, just before it spun off Poolbeg and when its business in conducting human challenge trials for treatments for infections and respiratory diseases was going gangbusters during the pandemic. Friel sold his final shares in the company a year ago.
[
Ireland's Mr IPO and his plans to make more companies public
Opens in new window
]
While the shares moved sideways for about four months after his exit, they have subsequently fallen more than about 60 per cent amid a cyclical downturn in clinical trials. This was accelerated in May when Hvivo told investors of the cancellation of a 'significant' contract and the postponement of another.
'When you see a founder selling, it's usually a signal. There was a massive bubble in clinical trials post pandemic,' he says. 'It's still a very good company. But it's a cyclical sector.'
Hvivo chief executive Yamin Khan gave an insight into working with Friel in
an interview with the Business Post last month
, after Friel stepped down as chairman. 'He hired me, he mentored me, [and I] really liked working with him,' he said. 'I think Cathal, he gets bored quite easily, he wants to do the next thing.'
[
Hvivo revenue rose last year as company diversified services
Opens in new window
]
Or ponder solutions on challenges facing business and society, which he often commits to published opinion pieces.
Take the Irish stock market, or Euronext Dublin, which has seen a wave of company exits and dearth of new listings over the past decade. 'It needs to be taken away from the orbit of the Department of Finance and given to the Department of Enterprise, Trade and Employment to develop ideas to reboot it. That department is in charge of two of the most successful state development bodies in the world – the IDA and Enterprise Ireland,' Friel offers.
Or the housing crisis. 'The Government should double all existing housing height limits overnight in every part of the country, make it more difficult for people to object to new housing developments and ban all judicial reviews on residential planning decisions.'
On artificial intelligence, he offers: 'It's here to stay. I'm convinced that, just like with the arrival of the motorcar and the PC revolution, AI will create far more jobs than it eliminates – and may even herald the arrival of formal four-day working week.'
While Friel is set to turn 61 later this year, he reckons he still has 'another 10 years in me' at Raglan.
'It's good fun. I always have to be planning the next deal. There's nothing imminent, but I'd likely to continue doing one every two or three years,' he says. 'First I've got to deliver the goods with Poolbeg and EGT.'
Name:
Cathal Friel
Position:
Founder of Raglan Capital, which has been behind five AIM-listed companies
Family:
Married to Pamela Iyers. They have two sons, aged 17 and 15, and a 13-year-old daughter
Lives:
Monkstown, south Co Dublin
Something about Cathal Friel that readers might expect:
Every summer, he spends a few weeks in Dunfanaghy, Co Donegal, fishing, boating and generally relaxing with his children while his wife enjoys a well-earned break with family in Austria
Something that might surprise:
He did close to 50 failed job interviews when he returned to Ireland after a year backpacking in Asia – before landing a job working for free for three months.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Irish Times
an hour ago
- Irish Times
Dublin children's hospital ‘misplaces' child's record in ‘serious data-protection breach'
A Dublin children's hospital has had a 'serious data-protection breach' after a patient's healthcare record was 'misplaced', a memo sent to staff said. It comes in the same week as an unannounced inspection by the Data Protection Commission (DPC) following concerns about the accessibility of patient charts in a shared office at Children's Health Ireland (CHI) Tallaght . On Friday, Sarah Hartnett, data-protection officer at CHI , sent a memo to all staff members entitled 'misplaced healthcare records'. 'A healthcare record has recently been reported misplaced at CHI. Despite a thorough search process, the original record has not been recovered,' the memo said. READ MORE 'In accordance with our statutory obligations, this incident has been reported to the Data Protection Commission'. According to Ms Hartnett, this is a 'serious data-protection breach and a reminder of the critical importance of following all healthcare record procedures'. 'Staff must strictly comply with the HSE standards for healthcare records management and CHI data-protection policies'. Separately, the DPC carried out an unannounced inspection at CHI Tallaght last week on foot of a complaint. The inspection took place in a shared office for non-consultant hospital doctors (NCHDs) on the first floor of the hospital. It is understood the door to the shared office, containing hundreds of patient charts, was propped open – making it accessible to people walking by. When closed properly, the door is locked with a keypad. Dr Turlough Bolger, a consultant in emergency medicine, sent an email to staff at the hospital on Thursday morning, the day after the inspection. 'The report will be received in the coming weeks but they expressed concern regarding the number of charts in the room yesterday (approx 320 charts) and the amount of loose pages with patient details,' his email states. 'I expect that the recommendations will be wide-ranging and damaging to CHI at Tallaght.' Dr Bolger said he appreciates the 'hard work' made by staff to reduce the number of outstanding discharge charts in recent weeks, which has seen a 'significant reduction' from 900 to 600 charts. 'I have said repeatedly that there needs to be a sustainable approach to this issue. Ultimately, as the accountable officer in CHI at Tallaght, I am responsible for the overall situation regarding medical records.' Dr Bolger said as the accountable officer, he 'cannot rely on blitzes to clear backlogs as routine'. In order to clear the current backlog, Dr Bolger said he had requested that four NCHDs be allocated to discharges daily. He added that there was a need for 'an emphasis on the use of the confidential shredding bin for most of the loose pages'. A spokesman for the DPC confirmed a team carried out an inspection at CHI Tallaght last week. 'Enquiries relating to this inspection are ongoing at present,' the spokesman said. 'We are not in a position to provide any further comment at this time.' In relation to the unannounced inspection, a spokeswoman for CHI said a data breach 'has not been confirmed at this time' and the inspection related to a 'potential data breach'. 'Immediate measures have been taken to reduce any potential risk, including reinforcing physical safeguards and engaging directly with staff,' the spokeswoman said. 'Additional actions will follow, as appropriate, in line with our internal procedures and any recommendations issued by the DPC as part of its broader oversight.' The spokeswoman added that CHI is transitioning to a 'fully digital health records system and, once complete, this will significantly reduce reliance on paper charts'. CHI has faced significant public and political scrutiny in recent months, particularly in relation to the governance and oversight of its paediatric orthopaedic services.


Irish Times
2 hours ago
- Irish Times
Hauliers accuse RSA of moving driving testers off commercial vehicles
Hauliers have accused the Road Safety Authority (RSA) of moving driving testers from articulated truck, bus and truck testing to car testing in order to reduce wait times for car driving tests, causing waiting times for commercial driving tests to increase. The Irish Road Haulage Association (IRHA) has presented its claims in a letter to Minister for Transport Darragh O'Brien and Minister of State at the Department of Transport Sean Canney. The group said waiting lists for car drivers fell by 10 per cent between April and June but that there was a significant increase in the wait times for truck (42 per cent) and articulated truck (40 per cent) tests over the same period. It said there was also a backlog for bus drivers. The RSA and the Department of Transport have been contacted for comment. READ MORE IRHA president Ger Hyland described the situation as 'a crisis in the making' for hauliers, and said the RSA came under 'intense political pressure' to move their testing resources from commercial testing into car testing, rather than expand their testing capabilities overall. The IRHA said the improvement in waiting times for car drivers and the increased backlog for commercial drivers coincided with a period during which Mr Canney met with RSA leadership and gave it a deadline to come up with proposals to improve driving test wait times. The group has now called for the driver testing system to be removed from the remit of the RSA. Mr Hyland accused the RSA of playing a 'dangerous game', describing it as 'effectively robbing Peter to pay Paul' at a time when the haulage sector is 'desperately short on drivers'. He said the delays were 'stifling economic growth' in rural Ireland by delaying the qualification of suitably qualified professional drivers who are 'desperately needed' to support small and medium sized businesses across the country. 'Young Irish drivers who need a license to drive a bus, truck or heavy goods vehicle (HGV) cannot get licenses because the RSA have all but stopped commercial testing to focus on car testing,' he said. 'They have pulled the wool over this Government's eyes and instead of dealing with the high demand for testing, they decided to simply move the deck chairs around the Titanic.' Mr Hyland claimed 'driving school owners' have told the group that commercial driving license testing in Ireland has 'all but stopped' over the past two months. 'That means no new bus drivers, truck drivers, HGV drivers,' he said. 'We have young Irish people who want to drive for a living but cannot get a license so we are forced to bring in drivers from South Africa instead whilst young Irish people are forced to move abroad and drive there – all because of the mismanagement of our testing system.' He said one HGV driving instructor in Kerry told the group he did not have a scheduled commercial driving test in the Tralee centre since May and wasn't expecting one until at least August. 'He told of the devastating impact this was having on his business and how he had young drivers waiting since January for a commercial driving test to try and get a job,' Mr Hyland added.


Irish Times
2 hours ago
- Irish Times
BP appoints Irishman Albert Manifold as new chairman
BP has appointed Irishman Albert Manifold as its new chair, paving the way for Helge Lund to depart after six troubled years steering the struggling UK oil major. Manifold, 62, was chief executive of building materials group CRH, a leading supplier of cement and concrete, for a decade until last December. The company moved its primary listing from London to New York in September 2023. 'He transformed and refocused CRH into a global leader,' said Amanda Blanc, the senior independent director at BP who led the process to find a successor for Lund. Manifold will join BP as chair-elect on September 1st and take over as chair the following month, accelerating Lund's timeline for leaving BP. At the start of April, BP said Lund planned to step down 'most likely during 2026'. READ MORE CRH's share price has risen by 74 per cent since it left the London Stock Exchange for the US. The Dublin-headquartered group said at the time of the switch that roughly three-quarters of its earnings came from North America and that the market was a key driver of future growth. The company, which supplies building materials to projects including the Burj Khalifa tower in Dubai and the expansion of the Paris metro, made $35.6 billion in revenue last year. Manifold is also a non-executive director at chemicals company LyondellBasell, which is in negotiations to sell four of its European plants amid a slide in its shares. In February, leading investors told the Financial Times that BP might also move its listing to New York in search of a 'deeper pool of capital', after activist investor Elliott Management took a stake in the company. BP's chief executive Murray Auchincloss said in April that the company had no current plans to move its listing. Lund, who was previously chief executive of Norway's Equinor and gas company BG Group, took over as BP chair in 2019 with a mandate to appoint a new chief executive and oversee a new strategy to guide BP through the energy transition. His efforts on both fronts ran into trouble. Lund's pick for chief executive, Bernard Looney, was dismissed in 2023 for failing to fully disclose to the board past relationships with BP colleagues. Earlier this year, BP abandoned Looney's plan to move away from oil and gas and reinvent itself as a green energy company. At the company's annual general meeting in April, a quarter of BP's investors voted against Lund's re-election in a largely symbolic protest. - Copyright The Financial Times Limited 2025